BioPharmaTrend
Latest Insights
Companies
  • Companies Directory
  • Case Studies
Newsletter
About
  • At a Glance
  • Our Team
  • Advisory Board
  • Citations and Press Coverage
  • Partner Events Calendar
  • Advertise with Us
 
 Subscribe 
Sign in
  • AI in Bio
  • Tech Giants
  • Next-Gen Tools
  • Biotech Ventures
  • Business Intelligence
Back to Companies Directory

Genuity Science (acquired by HiberCell)

Genuity Science logo

Website
https://genuitysci.com/
Founded
2013

Technologies

AI Companies (Drug Discovery)

Our products and services span study design, cohort sourcing, sample preparation, sequencing, secondary and tertiary analysis, storage (including cloud-based), interpretation, scalable analytics, and AI applied to genotypic and phenotypic data. All of these activities are built upon the proprietary GOR data platform and supported by the analysis of our expert team.

Our products and services span study design, cohort sourcing, sample preparation, sequencing, secondary and tertiary analysis, storage (including cloud-based), interpretation, scalable analytics, and AI applied to genotypic and phenotypic data. All of these activities are built upon the proprietary GOR data platform and supported by the analysis of our expert team.

More detail on our Artificial Intelligence Capabilities led by Dr Tom Chittenden:

- AI Specific to Biology: WuXi NextCODE ensemble AI approach is purpose-built and customizable to answer specific biological questions. Other companies use algorithms built in other fields which leads to information loss in the analysis and limits findings to mere correlations, rather than causation.

- Biological Validation of AI outputs: WuXi NextCODE biologically validates BVAI outputs in vitro and in mice to confirm the findings. Studies, including the recent Nature paper, show that our BVAI approach accurately predicts disease biology.

- Causal Dependency and NLP validation: WuXi NextCODE BVAI approach uses probabilistic programming to infer what bioprocesses cause downstream phenotypes, thus giving a clearer picture of potential drug targets and biomarkers.

genomics drug discovery

BiopharmaTrend.com

Where Tech Meets Bio
mail  Newsletter
in  LinkedIn
x  X
rss  RSS Feed

About


  • What we do
  • Press & Citations
  • Terms of Use
  • Privacy Policy
  • Cookies Policy
  • Disclaimer

Topics


  • News
  • AI in Bio
  • Tech Giants
  • Next-Gen Tools
  • Biotech Ventures

Explore


  • Premium Insights
  • Business Intelligence
  • Companies
  • Events
  • Authors

Partner


  • Sponsorship
  • Editorial Calendar

© WTMB Research & Media, S.L. (WTMB Group)   2026
We use cookies to personalise content and to analyse our traffic. You consent to our cookies if you continue to use our website. Read more details in our cookies policy.